CTI Welcomes Kentucky Governor Matt Bevin to Cut Ribbon at New Headquarters
The ribbon cutting ceremony will take place at CTI’s headquarters (100 E. RiverCenter Blvd., KY 41011) at 3:00pm EST. The event will include an address from the governor and remarks from Tim Schroeder, CEO of CTI, Bill Butler, Chairman and CEO of Corporex, and Kris Knochlemann, Judge Executive of Kenton county. Dan Tobergte from Northern Kentucky Tri-Ed will serve as master of ceremonies. Opportunities to take photographs and tour the facility will be available after the ribbon cutting.
“We are thrilled to welcome Governor Bevin to our new office,” says Tim Schroeder, CEO. “We have been working with the governor and his office on this project for more than a year, and we are very pleased to have them with us as we celebrate the grand opening of our new headquarters at RiverCenter Towers.”
Bexion and CTI Announce Completion of First-in-Human Trial Using BXQ-350 for the Treatment of Cancer
“CTI is extremely happy to partner with Bexion on the development of this novel therapy in patients who desperately need alternative treatments,” stated William Aronstein, PhD, MD, FACP, Vice President, Medical Affairs at CTI. “They are an innovative organization with very strong regional ties – the drug was initially developed and licensed at a local hospital, early funding has predominantly come from the region, and the management and board have strong local connections.”
CTI Announces Continued Growth Across Europe and Asia
“The expansions in Taiwan and Japan are part of continued efforts to increase capacity for clinical research across Asia,” according to Patrick Earley, Vice President, International. “We have been working across Asia for a number of years, but felt like a more permanent presence in Taipei and Tokyo would further enhance relationships with local medical centers and biotechnology companies.”
CTI Honored with Deal Maker Award
“We’re honored to be recognized by the Association for Corporate Growth Cincinnati with this award for CTI’s continued successes and innovations,” according to Timothy J. Schroeder, Founder and CEO. “This award is testament to our employees who work across the United States and in over 20 international countries that devote their lives to helping life-changing therapies reach critically and chronically ill patients around the world.”
Galectin Therapeutics and CTI Announce Positive New Psoriasis and Atopic Dermatitis Clinical Data
“We are very pleased to continue our collaboration with Galectin through this exciting trial that is showing promise for patients with severe skin diseases,” according to Joseph McCafferty, Vice President Global Business Development at CTI. “Dr. Traber and his Galectin colleagues have been tremendous to work with and we are privileged to be a partner on several of their life-changing programs.”
CTI Announces Site of New Global Headquarters
CTI will relocate its corporate headquarters from the Cincinnati suburb of Blue Ash, Ohio 17 miles south to Covington, Kentucky’s RiverCenter complex, where it will initially occupy approximately 125,000 square feet. The relocation will help the company consolidate its locations and facilitate future growth.
“As we continue to expand the company presence in the Tri-state area, we hope to become a model for other companies, in growing our footprint throughout this incredibly rich region. It is a transformative time in the company’s history, and we will look back positively on this decision and its impact on the company’s ability to move life-changing therapies to patients around the world, ” according to Timothy J. Schroeder, CTI Chief Executive Officer.